News

European GDP Association ernennt Alfred Hunt zum neuen Board-Mitglied und Deputy Chair

Die European GDP Association, die rund 3.500 Fachleute aus der ganzen Welt vertritt, hat ihren Vorstand erweitert. Alfred Hunt wurde eingeladen, dem Advisory Board beizutreten und hat die Rolle als stellvertretender Vorsitzender übernommen.

More
CJEU Judgement on OTC Medicines

In a recently published ruling, the Court of Justice of the European Union (CJEU) decided that a medicinal product not subject to medical prescription in one Member State may not automatically be placed on the market in another Member State. Rather, the medicinal product may only be placed on the market in a Member State if the competent authority of that Member State or the EU Commission has granted its marketing authorisation.

More
Acting as a Responsible Person (import) (RPi): MHRA concretises Eligibility Criteria

Last year, the Medicines and Healthcare products Regulatory Agency (MHRA) published a guidance called "Acting as a Responsible Person (import) ". The guidance describes the role of the Responsible Person (import) (RPi) and how to become a RPi. This guidance was now updated, listing extensive qualification requirements for RPi's.

More
European GDP Association nominates Alfred Hunt as new Advisory Board Member and Deputy Chair

The European GDP Association, representing about 3.500 professionals from across the globe, has extended its Board. Alfred Hunt was invited to join the Advisory Board and accepted to take over the role as a Deputy Chair.

More
EuGH-Urteil zu OTC-Arzneimitteln

Der Europäische Gerichtshof (EuGH) hat entschieden, dass ein Arzneimittel, das in einem EU-Mitgliedsstaat rezeptfrei verkauft werden darf, nicht automatisch auch in einem anderen Mitgliedstaat vertrieben werden darf. Das Arzneimittel darf vielmehr in einem Mitgliedstaat erst dann in den Verkehr gebracht werden, wenn die zuständige Behörde dieses Mitgliedstaats oder die EU-Kommission das Inverkehrbringen genehmigt.

More
EMA publishes Q&A Document about Parallel Distribution

Parallel distribution is defined as the distribution of a centrally authorised medicinal product from one Member State to another by a pharmaceutical company independent of the marketing-authorisation holder. In this context, the European Medicines Agency (EMA) has recently published a new comprehensive Q&A document containing answers to the most common questions.

More
Questions & Answers on Good Distribution Practices (GDP) - Part 5

In October 2020, the ECA Academy offered the Live Online Training "The GDP Compliance Manager". During the Q&A sessions, many interesting questions were posed to the speakers' team. The ECA would like to share a selection of these Q&As sorted by topic. Part 5 deals with questions related to deviations.

More
Neue Version der Q&As zu den Sicherheitsmerkmalen für Track & Trace

Die Europäische Kommission hat die Version 18b der  Q&As zu Sicherheitsmerkmalen veröffentlicht. Bei der Aktualisierung wurde insbesondere die neue ISO-Norm für Merkmale zur Verifizierung der Originalität berücksichtigt.

More
New Version of the Q&As on Safety Features for Track & Trace

The European Commission has published Version 18b of the "Questions & Answers" on safety features. In particular the update took into account the new ISO standard for Packaging Tamper verification features.

More
Recall of Product Samples from U.S. Market Due to Improper Storage Temperature Conditions

A global healthcare company is voluntarily recalling 1,468 product samples from the U.S. market because they were stored at temperatures below storage requirements. The products affected are used to lower blood glucose levels in people with diabetes. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

More
x
Search